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Glycosylation of immunoglobulin G is regulated by 
a large network of genes pleiotropic with  
inflammatory diseases
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Stuart J. McGurnaghan2, Toma Keser14, Frano Vučković1, Ivo Ugrina1,15, Jasminka Krištić1, 
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Julia Dmitrieva19, Mairead L. Bermingham2, Sodbo Zh. Sharapov3, Susan M. Farrington18, 
Evropi Theodoratou20,21, Hae-Won Uh16,22, Marian Beekman12, Eline P. Slagboom12, 
Edouard Louis23, Michel Georges19, Manfred Wuhrer16, Helen M. Colhoun2,24, Malcolm G. Dunlop18, 
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James F. Wilson2,20, Vlatka Zoldoš17, Veronique Vitart2, Tim Spector5, Yurii S. Aulchenko3,28,29‡, 
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Effector functions of immunoglobulin G (IgG) are regulated by the composition of a glycan moiety, thus affecting 
activity of the immune system. Aberrant glycosylation of IgG has been observed in many diseases, but little is under-
stood about the underlying mechanisms. We performed a genome-wide association study of IgG N-glycosylation 
(N = 8090) and, using a data-driven network approach, suggested how associated loci form a functional network. 
We confirmed in vitro that knockdown of IKZF1 decreases the expression of fucosyltransferase FUT8, resulting in 
increased levels of fucosylated glycans, and suggest that RUNX1 and RUNX3, together with SMARCB1, regulate 
expression of glycosyltransferase MGAT3. We also show that variants affecting the expression of genes involved 
in the regulation of glycoenzymes colocalize with variants affecting risk for inflammatory diseases. This study 
provides new evidence that variation in key transcription factors coupled with regulatory variation in glycogenes 
modifies IgG glycosylation and has influence on inflammatory diseases.
INTRODUCTION
Glycosylation, a series of reactions that creates complex carbohydrate 
structures (glycans) attached to a polypeptide backbone, is among 
the most common and complex posttranslational protein modifica-
tions. Highly regulated attachment of different glycans to the same 
glycosylation site (alternative glycosylation) can greatly contribute 
to variability in glycoprotein structure and influence function in a 
way that is analogous to changes in protein sequence (1). Immuno-
globulin G (IgG) is a simple glycoprotein with only one conserved 
N-glycosylation site per heavy chain and glycans that have no more 
than two antennae, but even this simple glycosylation has the capacity 
to generate hundreds of different glycoforms of IgG. It is well estab-
lished that alternative glycosylation of IgG can act as a molecular 
switch between different immune response outcomes and thus sig-
nificantly affect the function of the immune system (2). Aberrant 
protein glycosylation has been observed in many physiological states, 
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from aging- and age-related diseases to autoimmune diseases and 
cancer (3).
Glycans are synthesized in the endoplasmic reticulum and the 
Golgi apparatus by a complex interplay of glycosyltransferases—
enzymes that add monosaccharides to a growing glycan chain—and 
various other enzymes and transporters involved in synthesis and 
delivery of donors and substrates needed for chemical reactions (4). 
However, our understanding of the mechanisms by which alterna-
tive glycosylation is achieved and regulated is very limited.
N-linked glycans attached to a protein can be released, and their 
abundance can be quantified using a range of analytical methods. 
These measurements represent a set of quantitative traits character-
izing the glycome of the studied protein. As with any quantitative 
trait, the genetic determinants of the glycome can be studied by 
associating levels of glycans to polymorphic sequence variants mea-
sured in large cohorts of individuals [genome-wide association 
studies (GWAS)]. The first GWAS of the glycome identified associ-
ated variants in or near 7 glycosyltransferase genes and in 15 addi-
tional loci with no apparent role in protein glycosylation (5, 6). The 
list was recently extended by six additional loci (7, 8). However, there 
is still limited understanding of how these genes are functionally related 
or what their role is in the genetic regulation of IgG N-glycosylation 
in health and disease.
To address these questions, we performed the largest GWAS of 
the total IgG N-glycome to date, on 8090 samples from individuals 
of European ancestry, and more than doubled the number of asso-
ciated loci. To prioritize genes with a plausible role in IgG glycosylation, 
we assessed whether variants were located in the coding regions of 
genes, showed pleiotropy with gene expression in biologically rele-
vant cell types, and assessed enrichment in gene sets from different 
biological pathways. We explored how these genes are connected in 
a functional network and confirmed some of the network connec-
tions with in vivo functional follow-up. Last, we investigated pleiot-
ropy with other complex traits and diseases by interrogating the 
overlap of glycosylation associations with susceptibility loci for 
other phenotypes. Where available, we also assessed whether IgG 
N-glycosylation, diseases, and gene expression are likely to be con-
trolled by the same underlying causal variant using summary-level 
Mendelian randomization (SMR). This strategy not only resulted in 
the discovery of new candidate genes but also suggested how some 
of these genes could regulate glycosylation enzymes and how they 
could influence the aberrant glycosylation observed in diseases with 
an inflammatory signature.
RESULTS
Discovery and replication meta-analyses
We performed a discovery IgG N-glycosylation GWAS on four co-
horts of European descent (N = 8090). Associations of 77 ultraper-
formance liquid chromatography (UPLC) IgG N-glycan traits with 
HapMap2 (release 22) imputed genetic data were studied. We as-
sumed an additive linear model for each glycan trait, followed by a 
fixed-effect inverse-variance meta-analysis.
Overall, associations in 27 loci reached genome-wide significance 
[P ≤ 2.4 × 10−9; Bonferroni corrected for 21 independent glycan 
traits; (6)], and another 6 loci were suggestively significant (2.4 × 10−8 ≤ 
P < 2.4 × 10−9) (Table 1). Eight of the genome-wide significant loci 
confirmed previous findings from Lauc et al. (6), 5 confirmed those 
from Shen et al. (7) (one of which, AZI1, maps to the same locus as 
the suggestive association near SLC38A10 from Lauc et al.), and 1 
confirmed those from Wahl et al. (8) (Fig. 1 and table S1), while 14 
loci were not previously associated with IgG glycosylation. Individ-
ual associations and Manhattan plots can be found in the online 
resource available at https://shiny.igmm.ed.ac.uk/igg_glycans_gwas/. 
For 19 of 27 significant loci (9 of 14 previously unassociated), the 
same single-nucleotide polymorphism (SNP)–glycan association 
was replicated in a meta-analysis of four independent European 
cohorts (N = 2388) with P ≤ 0.05/27 ≈ 1.9 × 10−3. None of the genes 
in novel loci have a known role in glycosylation. For all loci, the 
direction of effect estimates obtained for the UPLC data (effect 
either increasing or decreasing with the same allele) was the same in 
the discovery and the replication parts of the study (Table 1).
To further validate our findings, we analyzed all significantly 
associated SNPs in a cohort where glycans were measured with 
liquid chromatography coupled to electrospray mass spectrometry 
(LCMS; N = 1842). From the 27 genome-wide significant SNPs, 17 
were associated with at least one of the LCMS-measured IgG glyco-
peptide levels at Bonferroni-corrected P ≤ 3.7 × 10−5. Of these 17, 
14 loci were also replicated in the UPLC replication study (table S2).
We performed an approximate conditional and joint analysis using 
GCTA-COJO (genome-wide complex trait conditional and joint 
analysis) software (9) to investigate secondary associations in the 
27 loci. We found evidence of multiple SNPs independently con-
tributing to glycan level variation for four loci. Three of these loci 
span glycosyltransferase genes, coding for enzymes directly involved 
in biosynthesis of glycans (4) (table S3). The greatest number of 
independently associated SNPs (six) was observed for the fucosyl-
transferase locus, FUT8, followed by three SNPs in the galactosyl-
transferase locus, B4GALT1, and two SNPs in the sialyltransferase 
gene, ST6GAL1. Two SNPs in the fourth locus, spanning the human 
leukocyte antigen (HLA) region on chromosome 6, are likely to be due 
to the complexity of this region, where multiple antigen-presenting 
genes are in close proximity and in high linkage disequilibrium (LD).
Using only the marginal effects of top SNPs, we were able to ex-
plain up to 20% of the genetic variance (for a single glycan trait). 
Uncovering additional variants in the conditional analysis resulted 
in a maximum of 22% variance explained. These maxima were 
reached for IGP29, the percentage of monosialylation of fucosylated 
digalactosylated structures without bisecting N-acetylglucosamine, 
GlcNAc (table S3).
Prioritizing genes associated with IgG N-glycosylation
We applied the following strategy to prioritize the most likely func-
tional genes. The Data-driven Expression Prioritized Integration for 
Complex Traits (DEPICT) framework (10) was used to perform a 
gene set and tissue/cell type enrichment analysis and to provide 
additional evidence for gene prioritization. Next, for all candidate 
genes in every locus, we explored evidence for genes containing SNPs 
affecting amino acid sequence using the Variant Effect Predictor 
(VEP) (11) and genes whose expression is likely to be regulated by 
the same underlying variant as N-glycosylation of IgG. For the latter, 
we applied SMR with heterogeneity in dependent instruments 
(HEIDI) (12) on expression quantitative trait loci (eQTLs) from five 
different immune cells (neutrophils, macrophages, B cells, and two 
types of T cells) from the CEDAR dataset [N = 350; Momozawa et al. 
(13)] and peripheral blood from Westra et al. (14) (N = 5311). This 
test assesses whether the coassociation of two traits to the same 
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Table 1. Loci associated with IgG glycosylation. Each locus is represented by the SNP with the strongest association in the region. Locus, coded by 
“chromosome: locus start–locus end” (GRCh37); No. of SNPs, maximum number of SNPs independently contributing to trait variation; SNP, variant with the 
strongest association in the locus; position, position of the SNP on the NCBI (National Center for Biotechnology Information) build 37; EA, allele for which effect 
estimate is reported; OA, other allele; EAF, frequency of the effect allele; R2, sample size weighted average of imputation quality for the SNP with the strongest 
association in the locus; glycan, glycan associated with the reported SNP; No. of glycans, number of other glycans suggestively or significantly associated with 
variants in given locus; , effect estimate for the SNP and glycan with the strongest association in the locus in the discovery; P, P value for the discovery effect 
estimate;  UPLC repl, effect estimate for the SNP and glycan with the strongest association in the locus in replication; P UPLC repl, P value for the effect estimate 
in replication. The loci replicated in UPLC replication at P ≤ 0.0019 are in bold. The loci from Lauc et al. (6), Shen et al. (7), and Wahl et al. (8) are in italics. 
Locus Candidate genes
No. of 
SNPs SNP EA OA EAF R
2 Glycan No. of glycans





25345011 RUNX3 1 rs10903118 T C 0.484 0.886 IGP74 13 −0.121 5.14 × 10
−13 −0.097 7.93 × 10−4
3:186712711-
186738421 ST6GAL1 2 rs7621161 A C 0.284 0.937 IGP29 27 −0.653 4.65 × 10
−276 −0.682 1.55 × 10−111
5:95211647-
95347786 ELL2 1 rs7700895 A T 0.215 0.997 IGP35 4 0.155 1.20 × 10




SLC22A4 1 rs11748193 A T 0.399 0.987 IGP2 2 0.110 4.31 × 10
−10 0.116 1.31 × 10−4
6:29299390-
33883424 HLA region 2 rs3099844 A C 0.136 0.995 IGP15 13 −0.227 1.12 × 10
−13 −0.083 2.28 × 10−1
6:139617590-
139636003 TXLNB 1 rs9385856 T C 0.574 0.977 IGP70 24 0.151 5.05 × 10
−19 0.111 1.54 × 10−4
6:143150223-
143203591 HIVEP2 1 rs7758383 A G 0.521 0.952 IGP13 3 0.125 9.61 × 10
−14 0.225 1.12 × 10−14
7:6520676-
6537913 DAGLB 1 rs6964421 T C 0.328 0.957 IGP14 7 0.117 5.31 × 10
−11 0.000 9.95 × 10−1
7:50325717-
50361683 IKZF1 1 rs6421315 C G 0.383 0.938 IGP62 37 0.192 4.70 × 10
−27 0.133 8.97 × 10−6
7:150906453-
150969535 ABCF2 1 rs7812088 A G 0.119 0.981 IGP2 16 −0.250 2.06 × 10
−22 −0.269 3.83 × 10−9
8:103538266-
103550211 ODF1 1 rs10096810 A G 0.627 1.000 IGP77 4 −0.110 9.52 × 10
−11 −0.074 1.37 × 10−2
9:33041761-
33186080 B4GALT1 3 rs10813951 A G 0.732 0.967 IGP17 30 0.230 8.84 × 10
−34 0.156 4.57 × 10−6
9:33205136-
33375592 SPINK4 1 rs12341905 A G 0.896 0.964 IGP53 4 0.168 1.46 × 10




NXPE1 1 rs481080 A G 0.475 0.999 IGP29 3 −0.140 1.05 × 10
−16 −0.099 5.28 × 10−4
14:65472891-
66284991 FUT8 6 rs11847263 T G 0.647 0.985 IGP42 16 −0.283 1.13 × 10
−58 −0.252 5.93 × 10−17
14:105966019-
106002352 TMEM121 1 rs4074453 T C 0.758 0.996 IGP48 6 −0.218 3.82 × 10
−29 −0.299 1.25 × 10−13
16:23397113-
23613191 GGA2-COG7 1 rs250555 T C 0.860 0.961 IGP26 4 −0.155 6.76 × 10













1 rs199456 T C 0.196 0.984 IGP14 7 0.162 6.76 × 10−14 0.136 9.18 × 10−4
17:45518583-
45874272 TBX21 1 rs11651000 A G 0.150 0.981 IGP59 8 −0.165 2.66 × 10






1 rs2725391 T C 0.460 0.974 IGP24 12 0.133 9.91 × 10−16 0.177 1.15 × 10−9
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traits or due to the variant being in LD with two independent causal 
variants, each exhibiting independent effects on each trait. More 
specifically, a pleiotropic scenario would assume that the same un-
observed variant is responsible for the association with both gene 
expression and glycan levels, while an LD scenario would assume 
that coassociation is due to two or more underlying variants that 
are in LD and independently contribute to either gene expression or 
glycan levels.
The DEPICT gene prioritization tool provided evidence of 
prioritization for 18 genes in 14 loci at false discovery rate (FDR) <0.05 
and another 3 genes at FDR <0.2 (Supplementary Note, Appendix 
Table 9). In four genes, associated variants were predicted to result 
in a potentially deleterious amino acid change, and in five genes, 
probably benign amino acid changes. SMR/HEIDI indicated that 
IgG N-glycosylation–associated variants in 9 loci had pleiotropic 
effects on expression of 13 genes in different tissues, including B cells 
(4 genes in 3 loci), the cell lineage responsible for IgG synthesis. For 
11 loci, we did not find any additional evidence to prioritize target 
genes and report the gene closest to the strongest association in the 
region (Fig. 1 and the Supplementary Note; https://shiny.igmm.ed.
ac.uk/igg_glycans_gwas/).
To obtain insights into the biological pathways that these genes 
are involved in, we performed FUMA’s GENE2FUNC (15) for Gene 
Ontology (GO) and DEPICT for gene set enrichment analyses. In 
total, our prioritized genes were significantly enriched in 75 different 
GO gene sets. These gene sets reflect three higher-level biological 
processes: glycosylation (23 gene sets), immune system processes 
(22 gene sets), and transcription (7 gene sets) (table S4). DEPICT 
tests for enrichment in preconstructed gene sets that are based on 
information from protein-protein interactions (PPIs), molecular and 
biochemical pathways, gene coexpression, and gene sets based on 
mouse gene knockout studies. No gene sets were enriched at FDR 
<0.05, but 397 gene sets were enriched at FDR <0.2. These gene sets 
are connected to various processes involved in immunity, B cell life 
cycle, and antibody production and quantity (table S5).
Functional network of loci associated with IgG 
N-glycosylation
Next, we investigated how genes in associated loci are functionally 
connected with each other. We assume that two loci with a similar 
glycome-wide effect (effect of the top SNP in the locus on all glycan 
traits) are likely to have a similar role in the regulation of glycosylation 
and may be a part of the same biological pathway. Our assumption 
is based on the following. We analyze the glycosylation of a single 
protein (IgG) and determine 77 different glycan traits. These traits 
arise as a result of the activity of different enzymes in the glycosylation 
biosynthesis pathway. It can be expected that changing the rate of 
a specific reaction would lead to specific changes of glycan profile, 
regardless of the specific mechanism (e.g., alteration in substrate 
availability, lower activity of enzyme as a result of a mutation chang-
ing its structure, a regulatory variation changing the level of expres-
sion of a gene encoding relevant enzyme), leading to the rate change. 
Locus Candidate genes
No. of 
SNPs SNP EA OA EAF R
2 Glycan No. of glycans




5845974 FUT6 1 rs874232 T C 0.565 0.971 IGP12 5 0.119 7.85 × 10
−13 0.070 2.08 × 10−2
19:19260586-
19296217 RFXANK 1 rs7257072 T C 0.515 0.997 IGP9 12 −0.122 1.59 × 10
−13 −0.068 1.97 × 10−2
20:17818141-
17833534 MGME1 1 rs2745851 A G 0.376 0.982 IGP38 10 −0.125 4.61 × 10
−13 −0.094 8.82 × 10−3
21:36546756-
36665202 RUNX1 1 rs7281587 A G 0.247 0.998 IGP45 19 −0.144 1.13 × 10







1 rs17630758 A G 0.152 0.991 IGP66 25 −0.308 1.20 × 10−41 −0.386 4.94 × 10−23
22:39774448-
39860868 MGAT3 1 rs5750830 A C 0.740 0.965 IGP40 28 −0.344 7.74 × 10
−69 −0.363 5.26 × 10−29
Suggestive
1:246854862-
246963137 LINC01341 1 rs3795464 A G 0.383 0.984 IGP73 2 −0.099 1.01 × 10
−08
2:100636757-





TNFRSF13B 1 rs4561508 T C 0.105 0.975 IGP9 2 0.163 5.70 × 10
−09
17:56398006-
56410041 MIR142 1 rs2526378 A G 0.549 0.935 IGP31 1 −0.100 4.44 × 10
−09
19:1614910-
1658699 TCF3 1 rs4807942 T C 0.878 0.661 IGP68 1 0.154 1.54 × 10
−08
20:52170177-
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For example, it can be expected that a regulatory variant that is 
associated with expression levels of glycosyltransferase gene MGAT3 
[mannosyl (-1,4-)-glycoprotein -1,4-N-acetylglucosaminyltransferase] 
will have an influence on all glycan traits that contain bisecting GlcNAc. 
This could be a variant changing the structure of this acetylglucos-
aminyltransferase, a regulatory variant in the promoter of the MGAT3 
gene, a variant disrupting an enhancer of MGAT3, or it could be a 
regulatory variant that changes expression of a transcription factor 
(TF) binding to the enhancer of MGAT3. Either way, the rate of 
reaction controlled by the product of MGAT3 would change, leading 
to a similar effect on all glycan traits that contain bisecting GlcNAc.
To create specific hypotheses regarding the regulatory functions 
of our loci, we defined the glycome-wide effect of an SNP as a vector 
of effects [in the form of z scores, where z score = /se()] of the 
given SNP on each of the glycans. As can be seen in fig. S1, some loci 
have notably similar effects on all glycan traits. We therefore con-
structed a functional network by computing Spearman pairwise 
correlations of glycome-wide effects of all 27 SNPs that tag each locus. 
Fig. 1. Gene prioritization in loci associated with IgG N-glycosylation. The Manhattan plot was created by taking the lowest P value at every genomic position from 
all 77 GWAS. For simplicity, the plot was trimmed at the equivalent of P = 10−50. The lowest observed P value in this analysis was 4.65 × 10−276 at ST6GAL1. Known loci, loci 
detected in previous IgG N-glycosylation GWAS; replicated, UPLC replication GWAS. Bottom: Summary of support for prioritization of every gene in the Manhattan plot. 
DEPICT, genes from enriched gene sets; expression, genes whose expression is pleiotropic with IgG N-glycosylation; CD19, B cells; PB, peripheral blood; coding, genes for 
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Given that the direction of the GWAS estimates depends on the 
allele used as a reference, the sign of correlation is not informative 
in this analysis. Therefore, we report absolute values of correlation 
coefficients. Although nodes in this network represent effects of top 
SNPs, we marked nodes by using the names of candidate genes in 
each locus, and we used these names to denote loci throughout the 
text. Below, we focus our discussion only on clusters that contain 
glycosyltransferases (MGAT3, FUT8, B4GALT1, and ST6GAL1), 
because these enzymes catalyze the transfer of monosaccharides 
to a growing glycan chain and therefore have a known and well- 
established role in the biosynthesis of glycans. As outlined above, we 
hypothesize that any locus with a similar glycome-wide effect to a 
glycosyltransferase locus is likely to either regulate the expression levels 
of the enzyme or modulate its activity through other indirect effects.
To validate the functional network, we applied both computa-
tional and experimental approaches. We first pruned the correlation 
network for significant correlations [P ≤ 0.05/(27 × 26)/2 ≈ 1.4 × 10−4] 
and performed permutation analysis with 100,000 random SNPs. 
We also compared our network with the STRING human PPI 
database (16).
The strongest overall correlation, a Spearman’s  of 0.97, was 
observed between IgG–N-glycome–wide effects of the top SNP in the 
MGAT3 locus and the top SNP in the SMARCB1-DELR3-CHCHD10- 
VPREB3 locus (Fig. 2A). None of the randomly selected SNPs 
exhibited such a strong correlation with these two loci in the permuta-
tion analysis (Table 2 and table S6). Recent work by Sharapov et al. 
(17) on genetics of the total plasma proteome N-glycosylation, of 
which IgG is a major part, suggested that the likely candidate 
gene is DERL3. DERL3 encodes a protein involved in endoplasmic 
reticulum–associated degradation for misfolded luminal glyco-
proteins. Data provided in this study shift the balance of evidence 
toward the SMARCB1, as it is unlikely that modulation of glyco-
protein degradation would result in effects similar to those observed 
when perturbing MGAT3.
The second strongest association, a Spearman’s  of 0.94, was 
between lead SNPs in TFs RUNX3 and RUNX1 loci. This link was 
validated in the permutation analysis and observed in the STRING 
PPI network. RUNX3 and RUNX1 loci were also strongly correlated 
with both the MGAT3 and SMARCB1-DELR3-CHCHD10-VPREB3 
loci (Table 2). A proxy for the top SNP in the MGAT3 locus, SNP 
rs8137426 (LD R2 = 1 with rs5750830), is located in a region bound 
by TF RUNX3, although not directly within its binding motif (fig. 
S2A). In our SMR/HEIDI analysis, we found evidence of the same 
association having a pleiotropic effect on both MGAT3 expression 
in CD19+ B cells and IGP40, a glycan trait related with bisecting 
GlcNAc (https://shiny.igmm.ed.ac.uk/igg_glycans_gwas/). This 
suggests that the associated SNP could influence binding of TFs 
(RUNX1 or RUNX3), which, together with the chromatin remodel-
ing protein SMARCB1, regulate expression of MGAT3, resulting 
in an increased incidence of bisecting GlcNAc in all fucosylated 
disialylated structures of IgG (IGP40; Table 1).
The FUT8 locus had the strongest glycome-wide association with 
the ORMDL3-GSDMB-IKZF3-ZPBP2 and IKZF1 loci ( = 0.71 and 
0.62). The latter two loci also show highly similar glycome-wide 
effects with each other ( = 0.78) and were observed as interacting 
in the STRING PPI network (Table 2 and table S7).
Two remaining galactosyltransferases had the strongest cor-
relations with loci where the underlying hypothesis of regulation 
is less straightforward. The most strongly correlated loci with the 
galactosyl transferase B4GALT1 locus were SPINK4 and HIVEP2 
( = 0.8 and 0.71). Top SNPs from the NXPE1-NXPE4 and ELL2 
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Fig. 2. Functional network of loci associated with IgG N-glycosylation. Correlation 
estimates are computed on the basis of squared pairwise Spearman’s correlation of 
SNP effects. The loci are denoted with names of genes that were prioritized in regions 
tagged by the given lead SNP. (A) Functional network of loci associated with IgG 
N-glycosylation. In this network, each node represents a lead SNP in the locus, and each 
edge represents the squared correlation of glycome-wide effects of the two nodes. 
Only significant correlations after multiple testing correction (P ≤ 1.4 × 10−4) are shown. 
The thickness and intensity of edges depend on variation in one locus explained by 
the effect estimates in the second locus. Round-edged rectangular nodes denote genes 
that are, according to GO, involved in glycosylation; purple-edged nodes denote 
genes involved in immune system processes; green nodes denote loci containing 
genes involved in transcription regulation; orange nodes denote glycosyltransferases; 
and blue rectangles indicate diseases pleiotropic with IgG glycans in the given locus 
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the sialyltransferase ST6GAL1 locus ( = 0.77 and 0.58). Full 
results of the permutation analysis and STRING PPI are avail-
able at the online resource (https://shiny.igmm.ed.ac.uk/igg_
glycans_gwas/).
Last, we assessed whether there is evidence of a subnetwork of 
genes regulating each specific glycosyltransferase by performing 
hierarchical clustering on the glycome-wide SNP effect correlation 
matrix. We observed three clusters: the cluster with MGAT3, the 
cluster with FUT8, and the cluster with B4GALT1 and ST6GAL1. 
Several loci containing genes coding for TFs cluster together with 
the MGAT3 locus, suggesting a complex regulatory network for this 
glycosyltransferase gene (and/or for the factors regulating this gene, 
i.e., RUNX1 is repressed by RUNX3) (Fig. 2B).
To further explore this possibility, we analyzed whether IgG 
glycosylation–associated SNPs were predicted to disrupt binding 
sites of TFs encoded by genes from this network more often than by 
chance. To assess the influence of glycosylation SNPs on binding 
of TFs from our network (IKZF1, IKZF3, RUNX1, RUNX3, IRF1, 
SMARCB1, and TBX21), we used Regulatory Sequence Analysis 
Tools (18). Briefly, if an associated SNP maps to the conserved 
position in the TF-binding motif and its effect allele is different than 
the conserved allele at that position, the SNP will be predicted to 
Table 2. In silico evidence for edges from functional network of IgG N-glycosylation loci. Permutation analysis was used to assess the distribution of 
glycome-wide SNP effect pairwise correlations and the STRING PPI database (16) to search for biological validation of observed links. All reported correlations 
are statistically significant after Bonferroni correction. Corr, Spearman’s correlation coefficient of z scores of SNP1 and z scores of SNP2; quant, quantile of 
distribution at which the given 2 was observed in permutation analysis; STRING score, probability that the link exists obtained by combining evidence from 
different sources. SNPs that were replicated in UPLC replication are in bold. 
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strongly affect binding of the TF. Alternatively, the allele can also 
completely disrupt or create the binding motif, resulting in a loss of 
a known or introduction of a new TF-binding site. In four loci span-
ning the glycosyltransferase genes, the associated SNPs resulted in 
either introduction or disruption of binding sites for TFs RUNX1, 
RUNX3, IKZF1, SMARCB1, TBX21, and IRF1. We observed the 
same disruption/introduction of TF-binding sites for all these TFs 
too and therefore confirmed some well-known regulation feedback 
loops between TFs RUNX1 and RUNX3 and IKZF1 and IKZF3 
(table S8) (19, 20). To assess whether these TF-binding site alter-
ations are specific for associated SNPs, we compared the frequency 
of TF-binding alterations of associated and nonassociated SNPs. In 
seven glycosylation loci, the associated SNPs were at least two times 
more likely to affect binding of TF than nonassociated SNPs from 
the same region. The highest difference in the number of SNPs affect-
ing the TF-binding site was observed for FUT8, MGAT3, and loci 
coding for TFs that are members of their cluster. Associated SNPs 
from the FUT8 and MGAT3 loci have a significant effect on binding 
of TF from our network, while nonassociated SNPs from their prox-
imity have no effect on binding (table S9). In summary, we not only 
found TFs associated with IgG glycosylation but also showed that 
glycosylation-associated SNPs can potentially alter their binding in 
other glycosylation-associated loci. These results not only reinforce 
some of the links suggested in our network but also confirm some 
known feedback loops between different TFs involved in B cell dif-
ferentiation and biology (e.g., interactions of IKZF1 and IKZF3 and 
RUNX1 and RUNX3) (19, 20).
Experimental validation of the functional links between 
IKZF1 and FUT8
Our network-based approach allowed us to show that variants in or 
near IKZF1 and IKZF3 share glycome-wide similarities with the top SNP 
in the FUT8 locus. We hypothesized that the TFs IKZF1 and IKZF3 
may regulate the expression of FUT8. We further observed notable 
pleiotropy between variants in the IKZF3-ORMDL3-GSDMB-ZPBP2 
locus with inflammatory conditions including inflammatory bowel 
disease (IBD), ulcerative colitis (UC), and rheumatoid arthritis (RA) 
(Fig. 2). We therefore aimed to disrupt this node of our network in 
our cellular model. Microarray and RNA sequencing data from the 
lymphoblastoid cell line (LCL) used in this study showed that IKZF1 
was more highly expressed than IKZF3. Because these genes are 
known to regulate one another, we decided to target IKZF1. To 
investigate the potential link between IKZF1 and FUT8, we identified 
IKZF1-binding sites on chromosome 14 near FUT8 in the LCL GM12878 
Encode chromatin immunoprecipitation sequencing (ChIP-seq) data. 
We performed ChIP followed by polymerase chain reaction (PCR) 
to confirm IKZF1 binding at one of these sites in an IgG-secreting 
human B cell–derived LCL, MATAT6 (Fig. 3A). We then investigated 
the role of IKZF1 in the regulation of FUT8 by conducting stable 
short hairpin RNA (shRNA)–mediated knockdown of IKZF1 using 
shRNA in MATAT6 cells. This resulted in depletion of the IKZF1 
transcript and protein (Fig. 3, B and C). Knockdown of IKZF1 was 
accompanied by a significant down-regulation of IKZF3 (Fig. 3D) 
and a 3.5-fold up-regulation in the expression of FUT8 (t test, P = 0.04; 
Fig. 3E), corroborating a link between IKZF1 and FUT8 and high-
lighting the dynamic relationships between TFs in B cells. Next, we 
looked at changes in the glycosylation of secreted IgG in cells with 
depleted IKZF1 at two different time points and observed a small 
but significant (P = 0.02; table S10) increase in fucosylation (Fig. 3F) 
resulting from IKZF1 knockdown. While this change is small, the 
low SE of triplicate measurements and independent replication 
of the experiment (second time point) demonstrate its robustness 
(table S10). In addition, one must consider that most of the glycans 
are fucosylated and that further fucosylation might be limited by 
specificities of glycosyltransferases involved in the process—the 
addition of bisecting GlcNAc to a growing glycan chain by MGAT3 
Fig. 3. Results of in vivo validation of the functional links between IKZF1 and FUT8. (A) IKZF1 binds to a regulatory region upstream of FUT8. (B) Knockdown of IKZF1 
leads to decreased expression of IKZF1 (n = 3). (C) Representative Western blot showing that IKZF1 is depleted at the protein level (protein reduced by around 50% compared 
with a random shRNA line or a non-IKZF1 targeting shRNA line). WB, Western blot. (D) Knockdown of IKZF1 leads to decreased expression of IKZF3 (n = 3). (E) Knockdown 
of IKZF1 leads to increased expression of FUT8 in the LCL (n = 3). (F) There is a small but significant increase in fucosylation of IgG secreted by the LCLs in which IKZF1 is 
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inhibits fucosylation of these glycans (21). This change also results 
in a 20% decrease (from 5 to 4%) in afucosylated glycans [glycoforms 
activating antibody-dependent cellular cytotoxicity (ADCC)]. These 
data are consistent with decreased expression of IKZF1 resulting in 
increased FUT8 expression and, thus, increased IgG fucosylation. 
Hence, although there is no in silico evidence that the lead SNP 
in the FUT8 locus overlaps with a predicted IKZF1-binding motif, 
and there is no evidence for the associated SNP being a FUT8 eQTL, 
we show that SNPs that are in LD with the lead FUT8 SNP can alter 
binding of IKZF1 (table S8). Furthermore, this TF can bind to 
regulatory regions of FUT8 and may act cooperatively with addi-
tional factors to modify its expression. To explore this further, 
we used publicly available Hi-C profiling performed at 1-kb resolu-
tion in the LCL GM12878. These data indicate that SNPs in the 
FUT8 locus lie in the same chromosomal topologically associat-
ing domain as the transcription start site of FUT8 (fig. S2B). 
CCCTC-binding factor (CTCF) plays a crucial role in maintaining 
the three-dimensional structure of the genome, and disruption of 
CTCF binding by SNPs in LD with rs4400971 may modify the inter-
actions formed between enhancer and promoter regions of FUT8 to 
affect expression of the glycosyltransferase enzyme (for details, see 
Supplementary Note).
Pleiotropy with complex traits and diseases
Because aberrant glycosylation patterns have been observed in 
various diseases (22–24), we explored pleiotropy between the 
glycosylation loci and other traits. We first searched for whether 
suggestive or significant glycosylation-associated SNPs and their 
proxies (PGWASglyco ≤ 2.4 × 10−8; LD R2 ≥ 0.8) were previously 
reported as associated (PGWAStraits ≤ 5 × 10−8) with other traits 
using Ensembl’s BioMart tool (25). Overall, 219 SNPs from 16 gly-
cosylation loci were reported to be associated with 83 other 
traits in various databases, 47 of which map outside the HLA region 
(chr6:29570005-33377657, GRCh37) (https://shiny.igmm.ed.ac.uk/
igg_glycans_gwas/).
To expand on the findings from Lauc et al. (6), where they report 
that some variants in LD with glycosylation variants are pleiotropic 
with diseases, we tested whether these coassociations may be due to 
the same underlying causal variant (pleiotropic) or are suggestive of 
LD between distinct causal variants each controlling different traits. 
We performed the SMR/HEIDI test on traits for which the full 
summary-level GWAS data were available. We excluded the HLA 
region from our analysis because of its complex LD structure, which 
is incompatible with this method’s sensitivity to LD. In total, we 
analyzed 10 traits (see details in Supplementary Note) and 55 glycan- 
trait combinations.
In three glycosylation loci, we found evidence for pleiotropy 
(PSMR ≤ 9.1 × 10−4, PHEIDI ≥ 0.05) between at least one IgG glycan 
and eight other diseases or traits [Crohn’s disease (CD), IBD, UC, 
RA, primary biliary cirrhosis (PBC), asthma, high-density lipopro-
tein (HDL) cholesterol, and Parkinson’s disease (PD)] and expres-
sion of GSDMB and ORMDL3 in B and T cells and IKZF3 and 
SLC22A4 in peripheral blood. In two glycosylation loci, SMR/
HEIDI analysis was more suggestive of LD rather than a pleiotropy 
scenario (PHEIDI ≤ 0.05), where different variants in the same locus 
are suggested to be causal for glycan levels and height and ankylos-
ing spondylitis (Table 3). Full results of the SMR/HEIDI test for 
complex traits can be found in the online resource https://shiny.
igmm.ed.ac.uk/igg_glycans_gwas/.
DISCUSSION
A recent study of the IgG glycome in 95 mouse strains from the collab-
orative cross cohort revealed that differences in glycosylation make 
IgG structure quite diverse between different strains (26). Despite the 
absence of a direct genetic template for individual glycans, these differ-
ences are heritable, indicating that glycoprotein structure is being in-
herited as a complex trait. The main enzymes involved in protein 
N-glycosylation are well characterized (4), but the genetic regulation 
of the process of glycosylation is poorly understood. To address this, 
we performed the largest GWAS of the IgG glycome to date, identify-
ing 27 loci and therefore doubling the number of previously associated 
loci. While 10 of these loci contain known glycosyl ation enzymes and 
other previously associated genes, 14 novel loci contain genes with no 
known role in glycosylation. We were able to explain as much as 22% 
of variance in glycan levels (for the degree of monosialylation of fuco-
sylated digalactosylated structures without bisecting GlcNAc, IGP29). 
Compared to previous studies, we do not just report the gene closest 
to the strongest association signal but have performed detailed analyses 
to seek the most biologically relevant annotation of our associated 
loci. Our candidate genes either have associated variants located in 
the coding regions of genes, show pleiotropy with gene expression 
in biologically relevant cell types, or are enriched in gene sets from 
appropriate biological pathways. We also explored how these genes 
are connected in a functional network, proposing mechanisms of the 
regulation of known glycosyl ation enzymes, and confirmed some of 
the network connections with in vitro functional follow-up.
As previously observed for GWAS of other complex traits, SNPs 
associated with IgG glycosylation predominantly map to noncoding 
regions of the genome, suggesting that regulatory variation at distal 
enhancers influences interindividual differences in glycan profiles. 
Several lines of evidence support this: the association of variants in 
or near genes coding for TFs, a high incidence of associated variants 
that are predicted to affect binding of those TFs, and pleiotropy be-
tween variants regulating the expression of the glycosyltransferases 
in B cells and IgG N-glycosylation. In addition, missense variants 
were observed only in genes without a previously known role in 
glycosylation and not in any glycosyltransferase genes where dam-
aging mutations are known to result in severe disease (27). IgG is 
synthesized and secreted by terminally differentiated B cells called 
plasma cells. Gene set enrichment analysis of our GWAS loci identi-
fied enrichment not only for GO terms associated with glycosylation 
and processes involved in the differentiation and maturation of B cells 
but also for GO terms associated with TF activity. This suggests that 
IgG N-glycosylation is more likely to be regulated at the level of 
expression of the main enzymes, their intracellular localization, or 
substrate availability than by impaired protein function.
We also capitalized on the omics setting of this study to create a 
data-driven network of the associated loci, suggesting mechanistic 
hypotheses on how new loci may influence known glycosyltransferases. 
We then used in vitro studies to validate selected findings. Within 
the network, most of the nodes clustered around a group of TFs 
known to have central roles in B cell maturation and differentiation: 
RUNX1 (28), RUNX3, IKZF1 (29), and IKZF3 (30). This clustering 
supports a TF-driven regulatory network acting in B lymphocytes 
to affect the expression of key glycosyltransferase enzymes. We 
hypothesized that associated SNPs would alter TF binding. In silico 
assessment in LCLs showed that glycosylation-associated SNPs alter 
binding of glycosylation-associated TFs in associated glycosyltrans-
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We identified seven loci as containing associated SNPs for which 
one allele disrupts a binding motif for at least one TF in our net-
work, two or more times more frequently than nonassociated SNPs 
from the same region. This is consistent with the identification of 
functionally important variants (or in LD with) in cis-regulatory 
elements acting to alter gene expression. For example, in our net-
work, we suggest that a number of TFs and chromatin remodeling 
proteins regulate expression of MGAT3, the enzyme that transfers a 
GlcNAc to the mannose core of N-linked oligosaccharides to pro-
duce bisecting GlcNAc glycan structures. We have provided in silico 
evidence that associated SNPs from the MGAT3 region disrupt bind-
ing sites for these TFs and are pleiotropic with MGAT3 expression 
in CD19+ B cells. In our network, we also observed a link between 
IKZF1 and FUT8. We provide direct evidence that IKZF1 transcrip-
tionally regulates FUT8, showing, first, that IKZF1 binds to regula-
tory regions of FUT8 and, second, that IKZF1 knockdown results in 
increased FUT8 expression and increased IgG fucosylation. We also 
observed a significant reduction in the expression of IKZF3 when 
IKZF1 was depleted, consistent with these TFs regulating one another 
(20) and explaining the similarity of their glycome-wide effects. The 
mechanism underlying the strong correlation between the glycome- 
wide effects of variants at other loci is less clear, highlighting the 
challenges in interpreting the effects of noncoding variants. Further 
work is required to determine exact mechanisms, although disrup-
tion of structural interactions or context-specific effects to stimuli is 
likely to be important.
Using glycosyltransferases as a positive control for gene prioriti-
zation, it is apparent that none of the methods used are sufficient in 
isolation, highlighting the complementarity and limitations of dif-
ferent approaches. In current databases and pathways, there is no 
information on the regulation of glycosyltransferases, so comple-
menting GWAS with data-driven network analysis, as performed 
here, can provide useful insights into potential mechanisms regulating 
genes of interest.
Aberrant glycosylation profiles were in the past observed in many 
diseases. An increase in agalactosylated structures is related to the 
proinflammatory effects of IgG (31). The absence of the core fucose 
is associated with increased ADCC (2, 32). Previous studies reported 
that some IgG glycosylation–related SNPs were also associated with 
a range of autoimmune diseases and hematological cancers (6, 7), but 
the mechanisms are still mostly unknown. We explored pleiotropy 
with complex traits and diseases and showed that diseases having 
the same associated SNPs are enriched in immune system disorders. 
Some of these diseases are also likely to have the same underlying 
causal variants as IgG N-glycosylation. In the ORMDL3-GSDMB-
IKZF3-ZPBP2 locus, we observed that risk for IBD, UC, CD, RA, 
PBC, asthma, and levels of HDL cholesterol increased with increas-
ing levels of afucosylated agalactosylated and monogalactosylated 
glycans (IGP2 and IGP6) and decreased with increasing levels of 
fucosylation for all diseases, except IBD and CD. This suggests that 
a more proinflammatory and pro-ADCC glycan profile is associated 
with increased risk for these diseases. A similar pattern of increased 
Table 3. Summary of the HEIDI testing for pleiotropy versus LD between variants coassociated with IgG glycan levels, complex traits, and gene 
expression. All traits have significant (PSMR ≤ 9.1 × 10−4) coassociation. In these loci where the associated variant was the same in IgG glycosylation, complex 
traits, and gene expression, we report only glycans pleiotropic with both expression and complex traits. The HEIDI test distinguishes between pleiotropy (shared 
causal variant, HEIDI P ≥ 0.05) or causal variants in LD (HEIDI P < 0.05). Glycan trait descriptions: G, galactose; F, fucose; N, bisecting GlcNAc; S, sialic acid; gene 
expression: CD4 and CD8, helper and cytotoxic T cells; CD19, B cells; PB, peripheral blood. 
Locus IGP Glycan description Complex traits SMR direction Gene expression SMR direction
Shared causal variant (pleiotropy)
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agalactosylated glycan traits was observed in epidemiological studies 
of patients with IBD, CD, UC (33, 34), and RA (35), and decreased 
fucosylation in UC, but not in CD (34).
In the same locus on chromosome 17, expression of GSDMB 
and ORMDL3 in peripheral blood and B and T cells—and of IKZF3 
in peripheral blood—followed the opposite pattern of association 
with IgG glycans to that for the disease risks. While these genes 
are not glycosyltransferases and therefore do not have a direct influ-
ence on glycosylation levels, we showed a direct link between 
the GSDMB-ORMDL3-IKZF3-ZPBP2 locus and FUT8 and in-
direct links with B4GALT1, potentially explaining how pleiotropy 
with genes previously unrelated to glycosylation could influence 
glycosylation and suggesting why specific glycans are altered in 
these diseases.
One drawback of this study is the use of a relatively old HapMap2 
imputation panel. However, at the onset of analyses, for many com-
plex traits and expression studies, summary association statistics 
were only available for older panels. Still, using a newer imputation 
panel or even whole-genome sequencing data would increase the 
power of the study to detect rarer variants not well tagged in the 
HapMap2 imputation.
B cell development requires a regulatory network driven by 
coordinated activity of TFs, the end point being antibody produc-
tion by plasma cells in response to antigen stimulus. The TFs IKZF1, 
IKZF3, RUNX1, and RUNX3 are lineage specific and have key roles 
in controlling the appropriate gene expression pattern at given time 
points, acting to both activate and repress gene expression and to 
alter the epigenetic landscape at functionally important genes. Fur-
thermore, their relative expression levels are dynamically and recip-
rocally regulated (19). A limitation of our network is that it is one 
dimensional; that is, it cannot delineate hierarchal relationships nor 
indicate at which stage during B cell development these interactions 
occur. Functional characterization of individual SNPs and of these 
putative enhancers to establish causality is beyond the scope of this 
study and remains to be explored.
In conclusion, we have shown that GWAS together with gene 
prioritization and data-driven network analysis is a powerful strategy 
for identifying biologically meaningful regulatory mechanisms 
underlying a complex biological process as is IgG glycosylation. The 
complexity of our functional network appears to reflect both the 
complexity of glycans themselves and the complex differentiation 
process that B cells undergo to reach the terminally differentiated 
state of IgG-producing plasma cells. However, it is clear that varia-
tion in key TFs coupled with regulatory variation in glycosylation 
enzyme genes drives changes in IgG glycosylation, modifying IgG 
function and influencing health and disease.
METHODS
All studies were approved by local research ethics committees, 
and all participants gave written informed consent. Details of 
participating cohorts, cohort-specific genotyping, quality control, 
and imputation performed before GWAS can be found in the 
Supplementary Note.
Isolation of IgG and glycan analysis
Isolation of IgG and glycan analysis has been described in detail in 
previous studies. An example protocol and details about each study 
can be found in the Supplementary Note. Briefly, IgG was first isolated 
using affinity chromatography binding to protein G plates, followed 
by release and labeling of glycans with 2-AB (2-aminobenzamide) 
fluorescent dye. Glycans were then separated and quantified by 
hydrophilic interaction UPLC, resulting in 24 chromatographic peaks. 
Most of the peaks contain a single glycan structure, while some con-
tain more than one, but with at least 63% of the peak being contrib-
uted by the most abundant glycan (36).
Phenotype preprocessing
To reduce experimental variation in glycan measurements, before 
genetic studies, raw glycan data were total area normalized and batch 
corrected using the “ComBat” function of “sva” (37) R package cen-
trally by the phenotype provider (Genos Ltd. for UPLC cohorts and 
Leiden University Medical Center for the Leiden Longevity Study). 




Discovery genome-wide association studies (GWAS) were performed 
in four cohorts of European descent, CROATIA-Korcula (N = 849), 
CROATIA-Vis (N = 802), ORCADES (Orkney Complex Disease 
Study) (N = 1960), and TwinsUK (N = 4479), with a combined sample 
size of 8090. Each glycan trait was first rank transformed to a normal 
distribution and then corrected for age, sex, cohort-specific covari-
ates, and cryptic relatedness using linear mixed models and a kinship 
matrix estimated from genotyped data (as appropriate in each spe-
cific cohort). Within each cohort, a genome-wide association scan 
was performed based on the HapMap2 (release 22) imputed genetic 
data (or corresponding subset from a newer reference panel), assum-
ing an additive linear model of association. Details of individual-level 
GWAS and parameters specific for each cohort can be seen in the 
Supplementary Note.
Cohort-level GWAS were examined for inconsistencies and in-
formative data using the EasyQC software package (38), and results 
were pooled and analyzed with METAL (39) using a fixed-effect 
inverse-variance meta-analysis method. Before meta-analysis, each 
GWAS was corrected for genomic control inflation factor. The ge-
nomic control inflation factor varied from 0.95 to 1.05, suggesting 
little residual influence of population stratification. Additional 
genomic control was performed on the aggregated meta-analysis 
results. As suggested by Winkler et al. (38), GWAS cleaning and 
meta-analysis were performed by two independent analysts, and the 
obtained effect size estimates and P values of the two meta-analyses 
displayed perfect concordance.
Multiple testing was controlled for by considering an association 
as genome-wide significant if the P value of association was ≤2.4 × 
10−9, as suggested by Li and Ji (40) and applied in Lauc et al. (6).
A locus was defined using the DEPICT tool (10) as a region 
spanned by SNPs in LD from the lead variant in the region. In cases 
where two such loci overlap, they were merged into a single locus.
Replication
Replication analysis was performed on 2368 samples from EGCUT 
(Estonian Genome Center, University of Tartu; N = 575), FINRISK 
(The National FINRISK Study; N = 552), COGS (Colorectal Cancer 
Genetics Susceptibility Study; N = 494), and SDRNT1BIO (Scottish 
Diabetes Research Network Type 1 Bioresource Study; N = 747). Top 
glycan–top SNP pairs from discovery meta-analysis from every 
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individual replication study and pooled using fixed-effect inverse- 
variance meta-analysis. The top SNP was defined as the SNP with 
the lowest P value in a locus. Replication significance level was set 
to P ≤ 1.9 × 10−3 (0.05 divided by the number of genome-wide 
significant loci, 27).
Additional validation was performed on glycosylation data mea-
sured with LCMS in the Leiden Longevity Study (N = 1842). Given 
that UPLC and LCMS measure similar but slightly different glycan 
traits (see “Validation genome-wide association studies” in the Sup-
plementary Note), it was not possible to replicate the same discovery 
SNP-glycan pairs. Instead, we looked at associations of the top SNP 
from every locus with any LCMS glycan, with an aim of replicating 
a locus rather than SNP-glycan association. Therefore, we set the 
significance level to P ≤ 3.7 × 10−5 [0.05/50/27—Bonferroni correction 
for 50 directly measured LCMS glycan traits, as used in Wahl et al. (8), 
and 27 loci].
GWAS of gene expression
Peripheral blood eQTL summary-level genome-wide statistics were 
downloaded from the SMR Results Database (41) in August 2016. 
Briefly, this study meta-analyzed gene expression quantified with 
Illumina arrays in 5311 samples and HapMap2 reference panel im-
puted genotypes (14).
We also used eQTL summary-level genome-wide statistics for 
six circulating immune cell types [CD4+ T lymphocytes, CD8+ 
T lymphocytes, CD19+ B lymphocytes, CD14+ monocytes, CD15+ 
granulocytes, and platelets from the CEDAR dataset; (13)].
Conditional analyses and variance explained
To test for the association of secondary SNPs while conditioning on 
the top SNP in the region, we performed conditional analysis on 
summary statistics from the discovery meta-analysis. Briefly, this 
method performs forward stepwise selection on summary-level data, 
where, based on an LD estimated from a reference dataset in each 
iteration, the SNP with the strongest association in the region is 
added in the regression model until no additional SNPs reach genome- 
wide significance. GCTA stepwise variable selection (9) was performed 
using more than 6000 unrelated individuals from the Generation 
Scotland (42) as an independent reference sample and restricting 
collinearity to 0.9, with P ≤ 2.4 × 10−9 as a genome-wide significance 
level. Reported joint P value was corrected with genomic control 
inflation factor .
For every independent SNPi, we calculated the proportion of ex-
plained phenotypic variance as
   i = 2 *  p i *  q i *   i 
2 
where i is the effect estimate of SNPi in univariate meta-analysis. 
and pi and qi are the minor and major allele frequencies of SNPi 
calculated in the Generation Scotland cohort, respectively. For 
each glycan that has at least one significantly associated SNP, we 
calculated total univariate explained variance as a sum of the pro-
portion of explained variance for all significant top SNPs for the 
given glycan.
To estimate the total variance explained by all independently 
contributing SNPs (total joint variance), we used the following pro-
cedure. For each glycan, we estimated the total joint variance by 
summing the contribution of each independently contributing SNP 
defined as
    i 
J = 2 *  p i *  q i *   i 
u *   i 
J
where   i 
u is the effect estimate of SNPi in the univariate analysis, and 
  i 
J is the joint effect estimate of the same SNP in the joint analysis.
Prioritizing genes associated with IgG N-glycosylation
For the genome-wide suggestive and significant loci, we explored 
potential causative genes at each locus using a strategy that combined 
publicly available datasets and prioritization tools and eQTLs from 
peripheral blood– and immune cell type–specific datasets.
Coding variation
To obtain the putative functional effect of associated variants, 
significantly or suggestively associated SNPs were annotated with 
VEP (11) in May 2016. Because of alternative splicing, each gene can 
have more than one transcript, and, consequently, depending on the 
transcript, one SNP can have a different effect on protein function.
SMR/HEIDI analysis for pleiotropy with gene expression
To test for potential pleiotropy between gene expression and IgG 
glycosylation, we performed SMR with HEIDI analysis, developed 
by Zhu et al. (12). SMR analysis provides evidence for pleiotropy 
but cannot distinguish if the associations are driven by the same or 
highly correlated but distinct causal variants. The subsequent HEIDI 
test allowed us to distinguish pleiotropy from LD. The test was 
performed on a publicly available peripheral blood dataset from 
Westra et al (14) and immune cell–specific gene expression from the 
CEDAR dataset (13). Among others, this dataset contains expression in 
B lymphocytes (CD19), helper T lymphocytes (CD4), cytotoxic T cells 
(CD8), macrophages (CD14), neutrophils (CD15), and platelets (PLA).
We set a threshold for the SMR test at PSMR ≤ 1.9 × 10−5, corre-
sponding to a Bonferroni correction for 2622 tests, number of re-
gions where genome-wide significant top regional IgG glycan SNP 
(or its proxy) was also available in any of the gene expression asso-
ciations. All regions with significant PSMR and PHEIDI ≥ 0.05 were 
considered to exhibit concordance in regional association pat-
terns and therefore showed evidence of sharing the underlying un-
observed causal variant. For these regions, we can suggest that 
they are pleiotropic. Details of the algorithm can be seen in the 
Supplementary Note.
Prioritization using DEPICT
DEPICT (10) was run on the merged list of independent SNPs ob-
tained from the GCTA-COJO analysis to identify gene sets enriched 
for genes near associated variants. Suggestive independent SNPs (P ≤ 
5 × 10−8) were submitted to DEPICT, release 194 (10). The list of 
independent SNPs was created by merging glycan-wise GCTA-COJO 
results, resulting in 113 SNPs. Given that different glycans can have 
a different lead SNP (but in high LD), this list was additionally pruned 
by applying PLINK clumping (43), where all SNPs within 500 kb and 
LD R2 > 0.1 of the SNP with the strongest association were assigned 
to the same clump. LD was estimated using 1000 Genomes Project 
Phase 1 CEU [Utah Residents (CEPH) with Northern and Western 
European Ancestry], GBR (British in England and Scotland), and 
TSI (Toscani in Italy) data.
Gene set enrichment analysis
GO enrichment analysis was performed using FUMA GENE2FUNC 
(15) analysis based on MSigDB c5 with default parameters and 
All genes as background genes. Glycosylation-related gene sets were 
defined as any GO gene set whose description contained words 
“glyc,” “sacch. fucose,” “carbo,” or “hexose.” Immune system–related 
gene sets were defined in the same manner, but searching for words 
“immune,” “B_CELL,” “lymphocyte,” “leukocyte,” “T_CELL,” 
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defined using the keywords “transcription” or “expression.” DEPICT 
pathways and tissue enrichments analyses were performed as 
described above.
Functional network of genes associated with  
IgG N-glycosylation
To suggest a functional relationship of loci associated with IgG 
glycosylation, we performed pairwise association analyses of glycome- 
wide effects of lead SNPs. Glycome-wide effect of the SNP was de-
fined as the vector of z scores [z score = /se()] of this SNP on each 
of glycans.
Before analysis, we removed 15 derived traits (IGP41 to IGP54) 
that represent directly measured glycans (IGP1 to IGP15) that were 
normalized with the surface area of neutrally charged glycans (see 
the Supplementary Note for details).
We then constructed glycome-wide effects for all 27 lead SNPs 
from the meta-analysis results for 62 glycans, resulting in 27 vectors 
of 62 z scores. For every pair of SNPs, we computed the Spearman’s 
correlation coefficient and corresponding P value between 27 
glycome-wide effects.
The network of significant Spearman’s correlations [P value cor-
rected for (27 × 26)/2 = 351 tests, P ≤ 1.4 × 10−4] was visualized 
using Cytoscape (44), where each node represents one lead SNP 
annotated with the gene prioritized in the region of that SNP and 
width and color intensity of edges present squared Spearman’s cor-
relation coefficient of the two nodes. We next performed clustering 
analysis of the full correlation matrix by applying hierarchical cluster-
ing with Euclidean distance and complete linkage. To validate the 
network, we performed permutation analysis and compared the 
network with STRING PPI networks (16).
The permutation analysis was performed by estimating the cor-
relation of glycome-wide effects of every top SNP and glycome-wide 
effects of 100,000 random SNPs. To ensure that no glycosylation- 
associated SNPs were included in the permutation analysis, the follow-
ing procedure was used. From the list of all HapMap release 22 SNPs 
(2,574,585 SNPs), all variants from the associated loci were removed, 
resulting in 2,510,568 remaining SNPs. An additional 6641 SNPs were 
removed because they had PGWAS ≤ 5 × 10−5 in at least one glycosyl-
ation GWAS. The final list contained 2,503,927 SNPs. From this list, 
100,000 SNPs were randomly selected for the permutation analysis. 
A Spearman’s correlation between glycome-wide effects of each of 
the 27 top SNPs with glycome-wide effects of 100,000 random SNPs 
was computed. These correlations were then compared with cor-
relations used to construct the network.
Additional validation was performed by comparing the network 
obtained by submitting IgG N-glycosylation candidate genes to the 
STRING database of PPIs (version 10.5, accessed in September 2017) (16).
ChIP-seq data (.narrowPeak files) for the TFs were downloaded 
from http://hgdownload.cse.ucsc.edu/goldenPath/hg19/encodeDCC/ 
for the GM12878 LCL. The peak-motifs tool (18) in the Regulatory 
Sequence Analysis Tools was used for motif discovery in the peak 
sequences of the ChIP-seq datasets. To assess whether glycosylation- 
associated SNPs disrupt or introduce TF-binding sites, we first 
filtered out all SNPs with no predicted effect on TF binding, with 
TF weight score P values higher than 1.8 × 10−8 (0.05/2,764,712, 
Bonferroni corrected for the number of tests performed). We then 
further filtered out the SNPs whose alternate alleles had similar 
TF-binding scores and focused on SNPs for which one allele results 
in loss of TF-binding site. To compare frequencies of TF-binding 
site disruptions of glycosylation SNPs and other SNPs in the region, 
we performed the same analysis using all significantly and sugges-
tively associated glycosylation SNPs (associated SNPs) and all SNPs 
within 50 kb of every glycosylation locus whose association P value 
was ≤5 × 10−4 (nonassociated SNPs) and compared frequency of 
SNPs that are predicted to significantly (Bonferroni-corrected P ≤ 
1.8 × 10−8) disrupt binding for the given TF.
Hi-C data derived from GM12878, digested with Mbo I, were 
interrogated using the online tool available at http://higlass.io/app/ 
(45). More details can be found in the Supplementary Note.
In vitro validation of the functional links between  
IKZF1 and FUT8
ShRNA cloning, cell culture, transfections, and shRNA knockdown
Four shRNAs targeting the coding region or the 3′ untranslated 
region of all IKZF1 isoforms were designed using Block-iT RNAi 
Designer (https://rnaidesigner.thermofisher.com/rnaiexpress/). 
Single-stranded oligonucleotides for IKZF1 shRNA and a sequence 
with no corresponding target in the human genome were annealed 
and cloned into pENTR/H1/TO vector and used for electroporation 
of an IgG1-secreting human LCL, MATAT6. RNA was extracted to 
assess gene knockdown efficiency for each shRNA tested by quanti-
tative PCR (qPCR), and the IKZF1 shRNA resulting in the most 
significant knockdown was used for subsequent experiments. More 
details can be found in the Supplementary Note.
RNA, complementary DNA, and real-time PCR
RNA was extracted from MATAT6 cells and stable shRNA lines, 
followed by on-column DNase (deoxyribonuclease) digestion and 
synthesis of complementary DNA and qPCR. qPCR gene expression 
assays were performed for IKZF1, FUT8, IKZF3, and HPRT1. Samples 
were run in triplicate. Relative gene expression level was determined 
using the comparative Ct (cycle threshold) method. Statistically sig-
nificant differences in gene expression were determined using the 
paired t test. More details can be found in the Supplementary Note.
Western blot analysis
Whole-cell lysates were prepared by lysing cells in radioimmuno-
precipitation assay buffer on ice. Jurkat nuclear extract and human 
embryonic kidney 293T lysates were used as positive and negative 
controls for IKZF1. Ten micrograms of total protein was reduced 
and denatured before separation on 4 to 12% Bis-Tris NuPAGE gel. 
Membranes were probed using rabbit polyclonal anti-Ikaros and 
mouse anti–-tubulin antibodies. Secondary antibodies were horseradish 
peroxidase–conjugated anti-rabbit IgG or anti-mouse IgG. Antibody 
detection was achieved using the enhanced chemiluminescence detec-
tion system. More details can be found in the Supplementary Note.
Glycan profiling of secreted IgG
Five million cells from stable bulk cultures of shRNA-expressing 
MATAT6 cells were washed in phosphate-buffered saline and then 
resuspended in (serum-free) Opti-MEM. After 72 hours, conditioned 
media were collected by centrifugation and immediately frozen at 
−80°C. The glycan profile of secreted IgG in samples collected on at 
least two occasions from IKZF1 shRNA lines (n = 3) or random 
shRNA lines (n = 2) was determined by LCMS as described under 
the validation LCMS study in the Supplementary Note. A paired 
t test (GraphPad QuickCalcs) was performed to assess significant 
differences in glycosylation features.
Chromatin immunoprecipitation
ChIP assays were performed using ExactaChIP buffers (R&D Systems), 
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described in the Supplementary Note. ChIP input was incubated with 
either anti-IKZF1 or goat IgG isotype control antibody overnight at 
4°C with rotation. Five micrograms of biotinylated anti-goat IgG 
was added for a further 2 hours before the addition of streptavidin- 
agarose beads. Agarose beads were collected by centrifugation. After 
the final wash, Chelating resin solution was added to the beads, and the 
samples were boiled for 10 min. ChIP-PCR was performed using primers 
flanking a binding site upstream of FUT8 identified by ChIP-seq 
analysis in the GM12878 cell line to confirm that IKZF1-DNA com-
plexes also occur in MATAT6 cells. PCR products were analyzed on 
2% (w/v) agarose gel by electrophoresis in tris-borate EDTA buffer.
SMR/HEIDI analysis for pleiotropy with complex traits
To assess regional association concordance between IgG glycosylation 
and other complex traits (SMR/HEIDI test), we were able to down-
load summary-level statistics including signed regression coefficient 
estimates and SE of these estimates for 10 traits (see the Supplementary 
Note for details). For each unique locus and glycan-trait combination 
for the test, we used only the SNP with the lowest P value in glycan 
GWAS. For all the available traits, the same procedure as outlined 
in the “SMR/HEIDI analysis for pleiotropy with gene expression” 
was applied.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/6/8/eaax0301/DC1
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